203 related articles for article (PubMed ID: 38426403)
41. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma.
He W; Sun Y; Ge J; Wang X; Lin B; Yu S; Li Y; Hong S; Xiao H
Front Endocrinol (Lausanne); 2023; 14():1076640. PubMed ID: 36843593
[TBL] [Abstract][Full Text] [Related]
42. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
43. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma.
Teng H; Mao F; Liang J; Xue M; Wei W; Li X; Zhang K; Feng D; Liu B; Sun Z
Theranostics; 2018; 8(16):4345-4358. PubMed ID: 30214625
[TBL] [Abstract][Full Text] [Related]
44. The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer.
Xia M; Wang S; Wang L; Mei Y; Tu Y; Gao L
Front Endocrinol (Lausanne); 2023; 14():1062317. PubMed ID: 37025405
[TBL] [Abstract][Full Text] [Related]
45. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
46. TRIM29 inhibits miR-873-5P biogenesis via CYTOR to upregulate fibronectin 1 and promotes invasion of papillary thyroid cancer cells.
Wu T; Zhang DL; Wang JM; Jiang JY; Du X; Zeng XY; Du ZX
Cell Death Dis; 2020 Sep; 11(9):813. PubMed ID: 32994394
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive analysis of cellular senescence and immune microenvironment in papillary thyroid carcinoma.
Huang Y; Jiang H; Xu G; Li X; Chen W; Lun Y; Zhang J
Aging (Albany NY); 2024 Feb; 16(3):2866-2886. PubMed ID: 38329430
[TBL] [Abstract][Full Text] [Related]
48. Tumor-Infiltrating Immune Cell Landscapes in the Lymph Node Metastasis of Papillary Thyroid Cancer.
Amanullah M; Pan M; Lu K; Pan X; Lu Y; Luo D; Liu P
Curr Oncol; 2023 Feb; 30(3):2625-2641. PubMed ID: 36975413
[TBL] [Abstract][Full Text] [Related]
49. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
50. Development of prognostic signatures for intermediate-risk papillary thyroid cancer.
Brennan K; Holsinger C; Dosiou C; Sunwoo JB; Akatsu H; Haile R; Gevaert O
BMC Cancer; 2016 Sep; 16(1):736. PubMed ID: 27633254
[TBL] [Abstract][Full Text] [Related]
51. Noncoding RNAs in Papillary Thyroid Cancer: Interaction with Cancer-Associated Fibroblasts (CAFs) in the Tumor Microenvironment (TME) and Regulators of Differentiation and Lymph Node Metastasis.
Dadafarin S; Carnazza M; Islam HK; Moscatello A; Tiwari RK; Geliebter J
Adv Exp Med Biol; 2021; 1350():145-155. PubMed ID: 34888848
[TBL] [Abstract][Full Text] [Related]
52. Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.
Luo D; Liu Y; Lin S; Tan L; Du Z; Long M; Zhu Y; Peng X; Zong W; Mackenzie GG; Li H; Ouyang N
Oncol Rep; 2019 Feb; 41(2):1253-1263. PubMed ID: 30535496
[TBL] [Abstract][Full Text] [Related]
53. Identification of
Zhang Y; Xie X; Zhou H; Li B; Ding L; Cai Z; Song H; Zhao S; Xu H
Front Endocrinol (Lausanne); 2023; 14():1131078. PubMed ID: 37455914
[TBL] [Abstract][Full Text] [Related]
54. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
55. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
56. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
57. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
58. Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract][Full Text] [Related]
59. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
60. Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk.
Song Y; Gao Z; Yan Z; Zheng C
Genes Genomics; 2022 Apr; 44(4):455-465. PubMed ID: 34860317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
